Skip to main content

Health news in Canada | CTV News | Canadian healthcare


Alzheimer's drug adoption in U.S. slowed by doctors' skepticism

Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among some doctors that treating the memory-robbing disease is futile.